References
- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583–96
- Falk R, Comenzo R, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898–909
- Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046–60
- Kramer M, van Dijk J, Hadas I, Hershko C. Destructive bone lesions in primary amyloidosis. Postgrad Med J 1986;62:1037–41
- Prokaeva T, Spencer B, Kaut M, Ozonoff A, Doros G, Connors LH, Skinner M, et al. Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis Rheum 2007;56:3858–68
- Mandl J. Uber lokales amyloid im bereiche der bruswirbelsaule. Virchows Arch fur Pathol Anat 1924;253:639
- Gerber I. Amyloidosis of the bone marrow. Arch Pathol 1934;17:620–30
- Axelsson U, Hallen A, Rausing A. Amyloidosis of bone: report of two cases. J Bone Jt Surg 1970;52B:717–23
- Cowan AJ, Seldin DC, Skinner M, Quillen K, Doros G, Tan J, O'Hara C, et al. Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftment. Biol Blood Marrow Transplant 2012;18:1935–8
- Lavatelli F, Perlman DH, Spencer B, Prokaeva T, McComb ME, Théberge R, Connors LH, et al. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics 2008;7:1570–83
- Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009;114:4957–9
- Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V L germ line gene use and clonal plasma cell burden. Blood 2001;98:714–20
- Schonland SO, Hansmann J, Mechtersheimer G, Goldschmidt H, Ho AD, Hegenbart U. Bone involvement in patients with systemic AL amyloidosis mimics lytic myeloma bone disease. Haematologica 2008;93:955–6
- Van Gameren II, van Rijswijk MH, Bijzet J, Vellenga E, Hazenberg BP. Histological regressin of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. Haematologica 2009;94:1094–100
- Zeier M, Perz J, Linke RP, Donini U, Waldherr R, Andrassy K, Ho AD, et al. No regression of renal AL amyloid in monoclonal gammopathy after succesful autologous blood stem cell transplantation and significant clinical improvement. Neprhol Dial Transplant 2003;18:2644–7
- Berenson BJR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 2014;16:593–602
- Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989–99
- Bouza C, López-Cuadrado T, Cediel P, Saz-Parkinson Z, Amate JM. Balloon kyphoplasty in malignant spinal fractures: a systematic review and meta-analysis. BMC Palliat Care 2009;8:12
- Olliff J, Hardy J, Williams M, Powles T. Magnetic resonance imaging of spinal amyloid. Clin Radiol 1989;40:632–3
- Faure C, Venin B, Bousquet J, Bochu M. Primary amyloidosis of bones. MRI aspects. J Radiol 1995;76:1025–7
- Alexandru D, So W. Evaluation and management of vertebral compression fractures. Perm J 2012;16:46–51